ARROWHEAD PHARMACEUTICALS, INC. Interest Expense Nonoperating
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Interest Expense Nonoperating of $24.56 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $24.56M, a 0.74% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $23.85M, a 10.20% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $22.50M, a 3.97% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $21.69M, a 48.11% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $89.36M, a 176.21% increase from fiscal 2024.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $32.35M, a 76.54% increase from fiscal 2023.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $18.33M.
- ARROWHEAD PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $0.00.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.56M 10-Q · filed 2026-08-04 | $48.41M derived: sum of 2 quarters · filed 2026-08-04 | $70.91M 10-Q · filed 2026-08-04 | $92.61M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $23.85M 10-Q · filed 2026-05-07 | $46.35M 10-Q · filed 2026-05-07 | $68.05M derived: sum of 3 quarters · filed 2026-05-07 | $92.43M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $22.50M 10-Q · filed 2026-02-05 | $44.20M derived: sum of 2 quarters · filed 2026-02-05 | $68.58M derived: sum of 3 quarters · filed 2026-08-04 | $90.22M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-09-30 | $21.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $46.08M derived: sum of 2 quarters · filed 2026-08-04 | $67.72M derived: sum of 3 quarters · filed 2026-08-04 | $89.36M 10-K · filed 2025-11-25 |
| 2025-06-30 | $24.38M 10-Q · filed 2026-08-04 | $46.02M derived: sum of 2 quarters · filed 2026-08-04 | $67.67M 10-Q · filed 2026-08-04 | $82.31M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $21.64M 10-Q · filed 2026-05-07 | $43.28M 10-Q · filed 2026-05-07 | $57.93M derived: sum of 3 quarters · filed 2026-05-07 | $63.03M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $21.65M 10-Q · filed 2026-02-05 | $36.29M derived: sum of 2 quarters · filed 2026-02-05 | $41.39M derived: sum of 3 quarters · filed 2026-02-05 | $48.63M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $14.65M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $19.74M derived: sum of 2 quarters · filed 2025-11-25 | $26.98M derived: sum of 3 quarters · filed 2025-11-25 | $32.35M 10-K · filed 2025-11-25 |
| 2024-06-30 | $5.09M 10-Q · filed 2025-08-07 | $12.34M derived: sum of 2 quarters · filed 2025-08-07 | $17.70M 10-Q · filed 2025-08-07 | $22.97M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $7.24M 10-Q · filed 2025-05-12 | $12.61M 10-Q · filed 2025-05-12 | $17.87M derived: sum of 3 quarters · filed 2025-11-25 | $23.03M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | $5.37M 10-Q · filed 2025-02-10 | $10.63M derived: sum of 2 quarters · filed 2025-11-25 | $15.79M derived: sum of 3 quarters · filed 2025-11-25 | |
| 2023-09-30 | $5.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $10.42M derived: sum of 2 quarters · filed 2025-11-25 | $18.33M 10-K · filed 2025-11-25 | |
| 2023-06-30 | $5.16M 10-Q · filed 2024-08-08 | $13.06M 10-Q · filed 2024-08-08 | ||
| 2022-09-30 | $0.00 10-K · filed 2024-11-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |